Other languages OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-16 pm EDT			5-day change	1st Jan Change
1.55 ^USD	+4.03%		+2.65%	-12.43%

Mar. 22	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
Mar. 22	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	Mar. 22
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	Mar. 20
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09
Sector Update: Health Care	Feb. 09
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	Feb. 09
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	Feb. 09
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	Jan. 31
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	Jan. 08
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	Dec. 04
Sector Update: Health Care Stocks Lean Lower Premarket Monday	23-10-09
OKYO Pharma Submits Investigational New Drug Application for OK-101 in Neuropathic Corneal Pain	23-10-09
Okyo Pharma Limited Announces Filing of an Investigational New Drug Application for Ok-101 to Treat Neuropathic Corneal Pain	23-10-09
OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease	23-10-05
Traders Digest Fresh Batch of Data, Stifling US Equity Futures Pre-Bell	23-09-15
Top Premarket Decliners	23-09-15
Sector Update: Health Care Stocks Rising Late Afternoon	23-09-14
Sector Update: Health Care Stocks Rising in Afternoon Trading	23-09-14
OKYO Pharma Prices $4 Million Share Offering	23-09-14
Top Premarket Decliners	23-09-14
OKYO Pharma Plans Share Offering; Stock Down After-Hours	23-09-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Other languages

Filters